69627-03-8

Usage

Uses

Used in Pharmaceutical Industry:
7-Chlorothieno[3,2-b]pyridine is utilized as a key building block for the synthesis of a range of pharmaceuticals and biologically active compounds. Its structural features allow it to be incorporated into diverse drug molecules, enhancing their therapeutic potential.
Used in Enzyme Inhibition:
7-Chlorothieno[3,2-b]pyridine is recognized for its potential as an enzyme inhibitor, which can be crucial in the development of treatments for various diseases where enzyme activity needs to be regulated.
Used as an Anti-Inflammatory Agent:
7-Chlorothieno[3,2-b]pyridine has shown promise as an anti-inflammatory agent, which could be beneficial in the management of conditions characterized by inflammation.
Used in Materials Science:
In the field of materials science, 7-Chlorothieno[3,2-b]pyridine has been studied for its potential use in the development of organic semiconductor materials, which could have applications in electronic devices and other advanced technologies.

InChI:InChI=1/C7H4ClNS/c8-5-1-3-9-6-2-4-10-7(5)6/h1-4H

Upstream product

• 34898-65-2 thieno<3,2-b>pyridine 4-oxide monohydrate 
• 104273-29-2 7-chlorothieno<3,2-b>pyridine 4-oxide 
• 69627-02-7 thieno[3,2-b]pyridin-7(4H)-one 
• 69627-02-7 thieno[3,2-b]pyridin-7-ol 
• 913377-45-4 2,2-dimethyl-5-{[(thiophen-3-yl)amino]methylidene}-1,3-dioxane-4,6-dione 
• 79-37-8 oxalyl dichloride 
• 272-67-3 thieno[3,2-b]pyridine 
• 104273-28-1 7-nitrothieno<3,2-b>pyridine 4-oxide 
• 90691-08-0 4,7-dihydro-7-oxothieno<3,2-b>-7(4H)pyridine-6-carboxylic acid 
• 69626-98-8 6-ethoxycarbonylthieno<3,2-b>pyridin-7(4H)-one 

Downstream Products

• 272-67-3 thieno[3,2-b]pyridine 
• 871690-72-1 3-fluoro-4-(thieno[3,2-b]pyridin-7-yloxy)aniline 
• 863783-87-3 5,6-Dimethyl-3-(thieno[3,2-b]pyridin-7-yloxy)-[2,2']bipyridine 
• 863784-22-9 2-Phenyl-3-(thieno[3,2-b]pyridin-7-yloxy)-[1,8]naphthyridine 
• 225385-05-7 2-bromo-7-chlorothieno[3,2-b]pyridine 
• 638219-98-4 7-chloro-2-methylthieno[3,2-b]pyridine 
• 638218-93-6 methyl 2-methyl-6-[thieno[3,2-b]pyridin-7-yloxy]benzofuran-3-carboxylate 
• 638219-78-0 2-methyl-6-(thieno[3,2-b]pyridin-7-yloxy)benzo[b]thiophene-3-carboxylic acid 
• 953130-97-7 1-(4-(2-(3-phenoxy-5-(thieno[3,2-b]pyridin-7-ylthio)pyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953042-36-9 tert-butyl 4-(5-(3-phenoxy-5-(thieno[3,2-b]pyridin-7-ylthio)pyridin-2-ylamino)-1,2,4-thiadiazol-3-yl)piperidine-1-carboxylate 
• 1033276-97-9 C₁₂H₇ClN₂S 
• 638217-82-0 7-chloro-2-pyrimidin-2-ylthieno[3,2-b]pyridine 
• 225385-12-6 7-chloro-2-(1,3-thiazol-2-yl)thieno[3,2-b]pyridine 
• 875340-07-1 7-chloro-2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridine 

Relevant academic research and scientific papers

Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors

The synthesis and biological evaluation of novel 1-aryl-3-[2-, 3- or 4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 3, 4 and 5 as VEGFR-2 tyrosine kinase inhibitors, are reported. The 1-aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas 4a-4h, with the arylurea in the meta position to the thioether, showed the lowest IC50 values in enzymatic assays (10-206 nM), the most potent compounds 4d-4h (IC50 10-28 nM) bearing hydrophobic groups (Me, F, CF3 and Cl) in the terminal phenyl ring. A convincing rationalization was achieved for the highest potent compounds 4 as type II VEGFR-2 inhibitors, based on the simultaneous presence of: (1) the thioether linker and (2) the arylurea moiety in the meta position. For compounds 4, significant inhibition of Human Umbilical Vein Endothelial Cells (HUVECs) proliferation (BrdU assay), migration (wound-healing assay) and tube formation were observed at low concentrations. These compounds have also shown to increase apoptosis using the TUNEL assay. Immunostaining for total and phosphorylated (active) VEGFR-2 was performed by Western blotting. The phosphorylation of the receptor was significantly inhibited at 1.0 and 2.5 μM for the most promising compounds. Altogether, these findings point to an antiangiogenic effect in HUVECs.

BIOMARKER-BASED THERAPEUTIC COMPOSITION

The present invention provides an anticancer agent for treating a patient who is resistant to a protein kinase inhibitor, the anticancer agent comprising, as an active ingredient, a thienopyridine derivative compound or a pharmaceutically acceptable salt thereof. Here, the patient may be a patient carrying active RON. In addition, the patient may be a patient carrying normal KRAS. In addition, the anticancer agent may be applied to a patient who is resistant to an EGFR inhibitor. In particular, the anticancer agent may be usefully used to treat a patient who is resistant to the therapeutic agent cetuximab.

NITROGEN-CONTAINING FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to a nitrogen-containing fused ring compound, a preparation method and use thereof. Specifically, the present invention relates to a compound having the structure of Formula (X), a stereoisomer, tautomer or mixture thereof, a pharmaceutically acceptable salt, co-crystal, polymorph or solvate thereof, or a stable isotope derivative, metabolite or prodrug thereof. The compound of the invention may have the structure of Formula (I) or Formula (II). These compounds are useful for the treatment of an abnormal cell proliferation disease (e.g., cancer). ????????R-L-R3?????(X)

Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

In our continuing efforts to develop novel c-Met inhibitors as potential anticancer candidates, a series of new N-sulfonylamidine derivatives were designed, synthesized via Cu-catalyzed multicomponent reaction (MCR) as the key step, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231). Most of the target compounds showed moderate to significant potency at both the enzyme-based and cell-based assay and possessed selectivity for A549 and HT-29 cancer cell lines. The preliminary SAR studies demonstrated that compound 26af (c-Met IC50 = 2.89 nM) was the most promising compound compared with the positive foretinib, which exhibited the remarkable antiproliferative activities, with IC50 values ranging from 0.28 to 0.72 μM. Mechanistic studies of 26af showed the anticancer activity was closely related to the blocking phosphorylation of c-Met, leading to cell cycle arresting at G2/M phase and apoptosis of A549 cells by a concentration-dependent manner. The promising compound 26af was further identified as a relatively selective inhibitor of c-Met kinase, which also possessed an acceptable safety profile and favorable pharmacokinetic properties in BALB/c mouse. The favorable drug-likeness of 26af suggested that N-sulfonylamidines may be used as a promising scaffold for antitumor drug development. Additionally, the docking study and molecular dynamics simulations of 26af revealed a common mode of interaction with the binding site of c-Met. These positive results indicated that compound 26af is a potential anti-cancer candidate for clinical trials, and deserves further development as a selective c-Met inhibitor.

Polysubstituted quinolone compounds, and preparation method and use thereof

The invention provides polysubstituted quinolone compounds, and a preparation method and a use thereof, and concretely provides a polysubstituted quinolone compound represented by formula I, and optical isomers, pharmaceutically acceptable salts or solvates thereof. All groups in the formula I are defined in the description. The quinolone compound has excellent c-Met inhibition activity, and can be used for treating c-Met activity or expression level corrected diseases.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS

Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.

ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention is for the anti-inflammatory compounds that have an inhibitory activity against protein tyrosine kinases and their pharmaceutical composition(s) containing the compound as the active ingredient. Since the compounds of the present invention can inhibit multiple protein kinases associated with inflammatory diseases and immune disorders, they are useful for their prevention or treatment.